U.S. markets close in 2 hours 26 minutes
  • S&P 500

    +57.83 (+1.41%)
  • Dow 30

    +339.15 (+1.00%)
  • Nasdaq

    +265.67 (+2.02%)
  • Russell 2000

    +41.62 (+1.92%)
  • Crude Oil

    +1.38 (+2.16%)
  • Gold

    +13.90 (+0.76%)
  • Silver

    +0.31 (+1.13%)

    +0.0056 (+0.46%)
  • 10-Yr Bond

    -0.0210 (-1.26%)

    +0.0044 (+0.31%)

    -0.0120 (-0.01%)

    +3,279.96 (+6.93%)
  • CMC Crypto 200

    +57.91 (+4.26%)
  • FTSE 100

    +80.28 (+1.15%)
  • Nikkei 225

    +636.46 (+2.32%)

Aquestive Therapeutics Announces Poster Presentations of Data on Libervant™ (diazepam) Buccal Film at American Epilepsy Society 2019 Annual Meeting

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Company to Host Scientific Exhibit on Monday, December 9 from 8:00 am ET to 11:00 am ET

Company to Host Investor & Analyst Libervant Update Forum and Webcast on Monday, December 9 at 4:00 pm ET

WARREN, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that data from five abstracts, including two “late-breakers”, related to its therapeutic candidate, Libervant™ (diazepam) Buccal Film, will be presented at the American Epilepsy Society (AES) 2019 Annual Meeting, taking place December 6-10, 2019 in Baltimore.

In addition to the poster presentations, Aquestive will host a Scientific Exhibit on Monday, December 9th from 8:00 am – 11:00 am ET at the Baltimore Convention Center in Rooms 318-319, Level 300. Study investigators and authors will be present to discuss the posters in more detail and answer questions.

Below is an overview of the poster presentations:

Title: Pharmacokinetics of Diazepam Buccal Film in Adult Patients with Epilepsy: Comparison with Diazepam Rectal Gel
Poster Number: 1.432
Presenter: Michael A. Rogawski, MD, PhD, Professor of Neurology and Pharmacology, School of Medicine, University of California, Davis
Date/Time: Saturday, December 7, 12 pm – 2 pm ET
Location: Hall E, Level 100

Title: Patient and Caregiver Preference for Route of Administration of a Benzodiazepine for Control of Increased Seizure Activity in Stable Patients
Poster Number: 2.129
Presenter: Ahmed Abdel-Razek, MD, Head of Medical Affairs, Aquestive Therapeutics
Date/Time: Sunday, December 8, 12 pm – 2 pm ET
Location: Hall E, Level 100

Title: Unreliable Absorption with Rectal Administration of Diazepam
Poster Number: 2.258
Presenter: Gary Slatko, MD, Chief Medical Officer, Aquestive Therapeutics
Date/Time: Sunday, December 8, 12 pm – 2 pm ET
Location: Hall E, Level 100

Title: Simulation of the Pharmacokinetics of Diazepam Buccal Film in Adult Patients with Epilepsy with Weight-adjusted Dosing
Poster number: 3.304
Presenter: Allen H. Heller, MD, MPH, Pharma Study Design LLC
Date/Time: Monday, December 9, 12 pm – 1:45 pm ET
Location: Hall E, Level 100

Title: Safety and Tolerability Associated with Chronic Intermittent Use of Diazepam Buccal Film in Pediatric, Adolescent, and Adult Patients with Epilepsy
Poster Number: 3.444
Presenter: Syndi Seinfeld, DO, MS, Associate Professor, Virginia Commonwealth University
Date/Time: Monday, December 9, 12 pm – 1:45 pm ET
Location: Hall E, Level 100

The posters will be accessible on the Newsroom section of the Aquestive website on the day of the presentations (Link).

Details of the Company’s Investor & Analyst Libervant™ Update Forum and webcast are as follows:
Date/Time: Monday, December 9 from 4:00 pm ET – 5:30 pm ET
Webcast and Presentation: The Investor & Analyst Libervant™ Update Forum will be webcast live and can be accessed from "Events and Presentations" in the Investors section of Aquestive's website (Link) on the day of the event.
Registration: In order to attend in person, please contact Stephanie Carrington at stephanie.carrington@icrinc.com.

About Libervant
Libervant is a buccally, or inside of the cheek, administered soluble film formulation of diazepam, a benzodiazepine intended for rapid treatment of acute uncontrolled seizures in selected, refractory patients with epilepsy on stable regimens of AEDs who require intermittent use of diazepam to control bouts of increased seizure activity. Aquestive is developing Libervant as an alternative to Diastat (diazepam rectal gel), the current standard of care rescue therapy for patients with refractory epilepsy, which as a rectal gel, is invasive, inconvenient, and difficult to administer. Libervant has received orphan drug designation from the FDA. Aquestive expects to complete its rolling NDA submission for Libervant around the end of November 2019.

About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. Aquestive has received conditional acceptance of the use of the trade name Libervant, which is subject to final FDA review and acceptance.

Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding therapeutic benefits and plans and objectives for regulatory approval of Libervant and other product candidates; statements about our growth and future financial and operating results and financial position, ability to advance Libervant and our other product candidates to the market, regulatory approvals and pathways, clinical trial timing and plans, short-term and long-term liquidity and cash requirements, cash funding and cash burn, business strategies, market opportunities, and other statements that are not historical facts.

These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials; risk of delays in FDA approval of our drug candidates or failure to receive approval; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk that a competitor obtains orphan drug exclusivity and blocks our product for the same indication for seven years; risk of development of our sales and marketing capabilities; risk of legal costs associated with and the outcome of our patent litigation challenging third party at risk generic sale of our proprietary products; risk of sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer term cash requirements and other cash needs, at the times and in the amounts needed; risk of failure to satisfy all financial and other debt covenants and of any default; risk related to government claims against Indivior for which we license, manufacture and sell Suboxone and which accounts for the substantial part of our current operating revenues; risks associated with Indivior’s announcement of its intention to cease production of its authorized generic buprenorphine naloxone film product, including the impact from loss of orders for the authorized generic product and risk of eroding market share for Suboxone and risk of sunsetting product; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance of our products and product candidates; the success of any competing products, including generics; risk of the size and growth of our product markets; risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to the Company's products; risk of unexpected patent developments; the impact of existing and future legislation and regulatory provisions on product exclusivity; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and risks that may arise regarding the safety or efficacy of the Company's products and product candidates; risk of loss of significant customers; risks related to legal proceedings, including patent infringement, investigative and antitrust litigation matters; changes in governmental laws and regulations; risk of product recalls and withdrawals; uncertainties related to general economic, political, business, industry, regulatory and market conditions and other unusual items; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section and in other sections included in the Company's Annual Report on Form 10‑K filed with the SEC on March 14, 2019 and in our quarterly reports on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

Investor inquiries:
Stephanie Carrington

Media inquiries
Mark Corbae